Acasti Pharma, Inc (ACST)

[CoolG73]

After rethinking this with a cold head here are my observations

1) they met their primary endpoint of delta higher than 20% , there is no point of issuing secondary numbers if the primary endpoint fails
2) it is possible that their delta is above 20% but less than 33%( vascepa) so they want to add the secondary success to show the trifecta effect that vascepa does not have, hence the delay waiting to get those secondary results
3) it is possible they really got delayed with the data processing and forgot to pass this info to the market ( I understood from someone they had the Xmas party so they forgot to issue the delay ), in this situation the original spike was the results leak coz by Friday they knew the results but needed the statistical consultants validation

In all scenarios I truly believe the primary endpoint was met